Comments on: 10 Things I’d Like to Start Hearing About Pharma Social Media http://www.doseofdigital.com/2010/07/10-like-starthear-pharma-social-media/ Improving Healthcare Through Digital Technology -- Effectively using digital technology and social media in pharma and healthcare Tue, 24 Jan 2012 00:11:00 +0000 hourly 1 http://wordpress.org/?v=3.3.1 By: Healthcare Agencies and Social Media: Start Here « Impactiviti blog http://www.doseofdigital.com/2010/07/10-like-starthear-pharma-social-media/#comment-9687 Healthcare Agencies and Social Media: Start Here « Impactiviti blog Tue, 14 Dec 2010 13:18:44 +0000 http://www.doseofdigital.com/?p=2799#comment-9687 [...] 10 Things I’d Like to Start Hearing about Pharma Social Media – Jon Richman [...] [...] 10 Things I’d Like to Start Hearing about Pharma Social Media – Jon Richman [...]

]]> By: Jonathan Richman http://www.doseofdigital.com/2010/07/10-like-starthear-pharma-social-media/#comment-8733 Jonathan Richman Mon, 26 Jul 2010 11:58:59 +0000 http://www.doseofdigital.com/?p=2799#comment-8733 Interesting point of view that I hadn't considered, which you point out: "The problem is that pharma patient advocacy execs are so stuck in old fashioned activities (e.g. hosted promotional events) that it is very difficult to make them listen to anything a little bit different." So, it's not just the pharma companies standing in the way, but the people who run these advocacy groups. I suppose in that way these senior people aren't much different than the senior people at a lot of companies. It takes a bit of a grassroots effort in these cases for something to change. This may mean a more junior person who knows the value of the space trying something different. I actually don't think the issue is this: "How can they convince pharma that it is worth spending money on their “disruptive” proposal?" I think that in the right venue and context pharma companies would be open to these ideas. They are, despite popular sentiment, looking for new ideas and love the chance to be the first to do something (assuming it's not too out there). The challenge is getting the idea in front of the right people. I think both groups are responsible for making this happen though. As it stands today, nothing will happen if neither side makes the first move. Interesting point of view that I hadn’t considered, which you point out: “The problem is that pharma patient advocacy execs are so stuck in old fashioned activities (e.g. hosted promotional events) that it is very difficult to make them listen to anything a little bit different.” So, it’s not just the pharma companies standing in the way, but the people who run these advocacy groups. I suppose in that way these senior people aren’t much different than the senior people at a lot of companies. It takes a bit of a grassroots effort in these cases for something to change. This may mean a more junior person who knows the value of the space trying something different.

I actually don’t think the issue is this: “How can they convince pharma that it is worth spending money on their “disruptive” proposal?” I think that in the right venue and context pharma companies would be open to these ideas. They are, despite popular sentiment, looking for new ideas and love the chance to be the first to do something (assuming it’s not too out there). The challenge is getting the idea in front of the right people. I think both groups are responsible for making this happen though. As it stands today, nothing will happen if neither side makes the first move.

]]> By: Jonathan Richman http://www.doseofdigital.com/2010/07/10-like-starthear-pharma-social-media/#comment-9439 Jonathan Richman Mon, 26 Jul 2010 11:58:00 +0000 http://www.doseofdigital.com/?p=2799#comment-9439 Interesting point of view that I hadn't considered, which you point out: "The problem is that pharma patient advocacy execs are so stuck in old fashioned activities (e.g. hosted promotional events) that it is very difficult to make them listen to anything a little bit different." So, it's not just the pharma companies standing in the way, but the people who run these advocacy groups. I suppose in that way these senior people aren't much different than the senior people at a lot of companies. It takes a bit of a grassroots effort in these cases for something to change. This may mean a more junior person who knows the value of the space trying something different. I actually don't think the issue is this: "How can they convince pharma that it is worth spending money on their “disruptive” proposal?" I think that in the right venue and context pharma companies would be open to these ideas. They are, despite popular sentiment, looking for new ideas and love the chance to be the first to do something (assuming it's not too out there). The challenge is getting the idea in front of the right people. I think both groups are responsible for making this happen though. As it stands today, nothing will happen if neither side makes the first move. Interesting point of view that I hadn’t considered, which you point out: “The problem is that pharma patient advocacy execs are so stuck in old fashioned activities (e.g. hosted promotional events) that it is very difficult to make them listen to anything a little bit different.” So, it’s not just the pharma companies standing in the way, but the people who run these advocacy groups. I suppose in that way these senior people aren’t much different than the senior people at a lot of companies. It takes a bit of a grassroots effort in these cases for something to change. This may mean a more junior person who knows the value of the space trying something different.

I actually don’t think the issue is this: “How can they convince pharma that it is worth spending money on their “disruptive” proposal?” I think that in the right venue and context pharma companies would be open to these ideas. They are, despite popular sentiment, looking for new ideas and love the chance to be the first to do something (assuming it’s not too out there). The challenge is getting the idea in front of the right people. I think both groups are responsible for making this happen though. As it stands today, nothing will happen if neither side makes the first move.

]]> By: epatientgr http://www.doseofdigital.com/2010/07/10-like-starthear-pharma-social-media/#comment-8721 epatientgr Sun, 25 Jul 2010 22:08:27 +0000 http://www.doseofdigital.com/?p=2799#comment-8721 “We’re using our social media resources to do something great for patient advocacy groups.” You give agreat example to pharma on what to do with patient advocacy groups. The problem is that pharma patient advocacy execs are so stuck in old fashioned activities (e.g. hosted promotional events) that it is very difficult to make them listen to anything a little bit different. So, you suggest that pharma takes the initiative to think more creatively in offering meaningful support to advocacy groups, but it is also possible that some advocacy groups come up with creative ideas out of the common path. How can they convince pharma that it is worth spending money on their "disruptive" proposal? “We’re using our social media resources to do something great for patient advocacy groups.” You give agreat example to pharma on what to do with patient advocacy groups. The problem is that pharma patient advocacy execs are so stuck in old fashioned activities (e.g. hosted promotional events) that it is very difficult to make them listen to anything a little bit different. So, you suggest that pharma takes the initiative to think more creatively in offering meaningful support to advocacy groups, but it is also possible that some advocacy groups come up with creative ideas out of the common path. How can they convince pharma that it is worth spending money on their “disruptive” proposal?

]]> By: epatientgr http://www.doseofdigital.com/2010/07/10-like-starthear-pharma-social-media/#comment-9438 epatientgr Sun, 25 Jul 2010 22:08:00 +0000 http://www.doseofdigital.com/?p=2799#comment-9438 “We’re using our social media resources to do something great for patient advocacy groups.” You give agreat example to pharma on what to do with patient advocacy groups. The problem is that pharma patient advocacy execs are so stuck in old fashioned activities (e.g. hosted promotional events) that it is very difficult to make them listen to anything a little bit different. So, you suggest that pharma takes the initiative to think more creatively in offering meaningful support to advocacy groups, but it is also possible that some advocacy groups come up with creative ideas out of the common path. How can they convince pharma that it is worth spending money on their "disruptive" proposal? “We’re using our social media resources to do something great for patient advocacy groups.” You give agreat example to pharma on what to do with patient advocacy groups. The problem is that pharma patient advocacy execs are so stuck in old fashioned activities (e.g. hosted promotional events) that it is very difficult to make them listen to anything a little bit different. So, you suggest that pharma takes the initiative to think more creatively in offering meaningful support to advocacy groups, but it is also possible that some advocacy groups come up with creative ideas out of the common path. How can they convince pharma that it is worth spending money on their “disruptive” proposal?

]]> By: Shareworthy: Four “can’t miss” clicks « Brand Liberators Blog http://www.doseofdigital.com/2010/07/10-like-starthear-pharma-social-media/#comment-8538 Shareworthy: Four “can’t miss” clicks « Brand Liberators Blog Mon, 19 Jul 2010 13:27:51 +0000 http://www.doseofdigital.com/?p=2799#comment-8538 [...] do that!” comes this great find from fellow blogger Jon Richman. In his mini-white paper 10 Things I’d Like to Start Hearing About Pharma Social Media, Jon shares this very cool search and response Twitter campaign by [...] [...] do that!” comes this great find from fellow blogger Jon Richman. In his mini-white paper 10 Things I’d Like to Start Hearing About Pharma Social Media, Jon shares this very cool search and response Twitter campaign by [...]

]]> By: Shareworthy: Four “can’t miss” clicks | What's Your Digital iQ? http://www.doseofdigital.com/2010/07/10-like-starthear-pharma-social-media/#comment-8537 Shareworthy: Four “can’t miss” clicks | What's Your Digital iQ? Mon, 19 Jul 2010 13:23:13 +0000 http://www.doseofdigital.com/?p=2799#comment-8537 [...] do that!” comes this great find from fellow blogger Jon Richman. In his mini-white paper 10 Things I’d Like to Start Hearing About Pharma Social Media, Jon shares this very cool search and response Twitter campaign by [...] [...] do that!” comes this great find from fellow blogger Jon Richman. In his mini-white paper 10 Things I’d Like to Start Hearing About Pharma Social Media, Jon shares this very cool search and response Twitter campaign by [...]

]]>